Harlan Labs names new CEO
The Indianapolis-based provider of clinical research animals has promoted senior manager Hans Thunem to its top spot.
Pharmaceutical
Articles
Drug prices rise ahead of rebates
Drug prices rose faster last year than they have in a decade—just in time for big rebates the drug industry promised
as part of the health reform law.
Lilly to pay $400M to repurchase Cymbalta rights
Eli Lilly and Co. will repurchase rights to develop and market antidepressant Cymbalta outside the U.S. and Japan from European
partner Boehringer Ingelheim for an initial payment of $400 million.
Lilly diabetes drug may have cancer risk, FDA says
Once-weekly form of Byetta is awaiting the FDA’s OK. Analyst predict the new version of the drug, if approved, could rack
up sales of $2 billion annually.
Louisiana gets $20M in Lilly drug settlement
Louisiana was one of 13 states that filed individual suits in state courts over allegations that Lilly pushed Zyprexa for
uses that had not been approved by federal regulators.
Lilly wins court ban on generic copy of Gemzar
Eli Lilly and Co. won a U.S. court ruling Wednesday that bars Teva Pharmaceutical Industries Ltd. from selling a generic version
of the cancer drug Gemzar until November.
Lilly drug wins U.K. backing as cancer therapy
Eli Lilly and Co.’s Alimta has received the preliminary backing of a United Kingdom agency as a maintenance treatment for
patients with the most common form of lung cancer.
Lilly to let 115 workers go in new outsourcing deal
Deal with unit of Massachusetts-based Thermo Fisher Scientific would keep many of the employees working in same
location.
Lilly sues Hospira over generic version of Gemzar
Indianapolis-based Eli Lilly and Co. sued rival drugmaker Hospira Inc. to prevent it from selling a generic version of the
cancer drug Gemzar before a patent on the medicine expires in 2013.
Ariad loses $65M patent appeal against Eli Lilly
Monday’s decision throws out a $65.2 million patent-infringement verdict won by Ariad for royalties on Lilly’s osteoporosis
drug Evista and sepsis medicine Xigris.
Bill kicks off years of change for local health care players
Sweeping changes phase in slowly for most, but insurers, hospitals, drug companies, employers, workers, medical device makers
and more will eventually feel impact.
Reform offers risk, opportunities for Lilly, WellPoint
Drugmakers and insurers could gain millions of customers under the legislation, but the industry also will pay new fees and
face stricter rules that may shrink profit and fuel mergers.
Lilly sues to block generic of Adcirca lung treatment
Netherlands-based Synthon Pharmaceuticals is seeking U.S. Food and Drug Administration approval to sell a copy of the medicine.
Lilly victim of theft from Connecticut warehouse
Pharmaceuticals stolen Sunday morning could be worth up to $75 million.
Lilly buys right to underarm lotion for low sex drive
Eli Lilly & Co., the maker of the impotence pill Cialis, bought exclusive rights from Australia’s Acrux Ltd. to
an underarm testosterone lotion called Axiron for men with limited sex drive due to low levels of the hormone.
Lilly pays $50M-plus for rights to testosterone lotion
Indianapolis-based Lilly will pay Acrux of West Melbourne, Australia, a $50 million license fee, plus $3 million when manufacturing
assets are transferred, but the deal could be worth millions more.
FDA says ‘not yet’ on Lilly’s once-weekly Byetta
Regulators won’t require more time-consuming tests of the drug, but want Eli Lilly and Co. and its partners to clarify labeling,
manufacturing
processes.
Cornelius to retire as Bristol-Myers Squibb CEO
The former Guidant Corp. CEO and long-time Eli Lilly exec said he and his family will be returning to Indianapolis.
Lilly, Transition Therapeutics make diabetes deal
Drug developer Transition Therapeutics Inc. said Wednesday that it will pay $1 million to license a group of potential diabetes
drugs from Eli Lilly and Co.
Obama health reform plan slaps drugmakers
Drugmakers, such as Indianapolis-based Eli Lilly and Co., would shoulder $3.3 billion in fees, face ban on pay-for-delay deals
with generic competitor.